• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

补体在阿尔茨海默病中的作用:从遗传学、病理学到治疗策略

Involvement of Complement in Alzheimer's Disease: From Genetics Through Pathology to Therapeutic Strategies.

作者信息

Daskoulidou Nikoleta, Carpanini Sarah M, Zelek Wioleta M, Morgan B Paul

机构信息

UK Dementia Research Institute Cardiff, Cardiff University, Cardiff, UK.

出版信息

Curr Top Behav Neurosci. 2025;69:3-24. doi: 10.1007/7854_2024_524.

DOI:10.1007/7854_2024_524
PMID:39455500
Abstract

Complement is a critical component of innate immunity, evolved to defend against pathogens and clear toxic debris ranging from dead and dying cells to immune complexes. These roles make complement a key player in homeostasis; however, complement has a dark side. When the rigid control mechanisms fail, complement becomes dysregulated, acting as a driver of inflammation and resultant pathology in numerous diseases. Roles of complement in Alzheimer's disease (AD) and other dementias have emerged in recent years, supported by genetic, biomarker and pathological evidence and animal model studies. Numerous questions remain regarding the precise roles of complement in the brain in health and disease, including where and when complement is expressed, how it contributes to immune defence and garbage disposal in the healthy brain, and exactly how complement contributes to pathology in dementias. In this brief review, we will summarise current knowledge on complement roles in brain, present the evidence implicating complement in AD and explore whether complement represents an attractive therapeutic target for AD.

摘要

补体是先天免疫的关键组成部分,其进化目的是抵御病原体并清除从死亡和濒死细胞到免疫复合物等各种有毒碎片。这些作用使补体成为体内平衡的关键因素;然而,补体也有不利的一面。当严格的控制机制失效时,补体就会失调,在许多疾病中成为炎症和由此导致的病理状态的驱动因素。近年来,补体在阿尔茨海默病(AD)和其他痴呆症中的作用逐渐显现,这得到了遗传学、生物标志物、病理学证据以及动物模型研究的支持。关于补体在大脑健康和疾病中的精确作用,仍有许多问题,包括补体在何处以及何时表达、它如何在健康大脑中促进免疫防御和垃圾处理,以及补体究竟如何导致痴呆症中的病理状态。在这篇简短的综述中,我们将总结关于补体在大脑中作用的现有知识,展示补体与AD相关的证据,并探讨补体是否是AD有吸引力的治疗靶点。

相似文献

1
Involvement of Complement in Alzheimer's Disease: From Genetics Through Pathology to Therapeutic Strategies.补体在阿尔茨海默病中的作用:从遗传学、病理学到治疗策略
Curr Top Behav Neurosci. 2025;69:3-24. doi: 10.1007/7854_2024_524.
2
A Novel Design of a Portable Birdcage via Meander Line Antenna (MLA) to Lower Beta Amyloid (Aβ) in Alzheimer's Disease.一种通过曲折线天线(MLA)设计的便携式鸟笼,用于降低阿尔茨海默病中的β淀粉样蛋白(Aβ)。
IEEE J Transl Eng Health Med. 2025 Apr 10;13:158-173. doi: 10.1109/JTEHM.2025.3559693. eCollection 2025.
3
18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代甲磺酸去甲肾上腺素的18F正电子发射断层显像用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012884. doi: 10.1002/14651858.CD012884.
4
Short-Term Memory Impairment短期记忆障碍
5
The Black Book of Psychotropic Dosing and Monitoring.《精神药物剂量与监测黑皮书》
Psychopharmacol Bull. 2024 Jul 8;54(3):8-59.
6
CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).脑脊液tau蛋白及脑脊液tau蛋白与β淀粉样蛋白比值在轻度认知障碍(MCI)患者中用于诊断阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Mar 22;3(3):CD010803. doi: 10.1002/14651858.CD010803.pub2.
7
¹⁸F-FDG PET for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).¹⁸F - 氟代脱氧葡萄糖正电子发射断层显像(¹⁸F - FDG PET)用于轻度认知障碍(MCI)患者中阿尔茨海默病性痴呆及其他痴呆的早期诊断。
Cochrane Database Syst Rev. 2015 Jan 28;1(1):CD010632. doi: 10.1002/14651858.CD010632.pub2.
8
Speech changes in old age: Methodological considerations for speech-based discrimination of healthy ageing and Alzheimer's disease.老年言语变化:基于言语的健康衰老与阿尔茨海默病鉴别方法学的考虑。
Int J Lang Commun Disord. 2024 Jan-Feb;59(1):13-37. doi: 10.1111/1460-6984.12888. Epub 2023 May 4.
9
18F PET with florbetapir for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI).使用氟代硼吡咯进行18F正电子发射断层显像以早期诊断轻度认知障碍(MCI)患者的阿尔茨海默病性痴呆及其他痴呆。
Cochrane Database Syst Rev. 2017 Nov 22;11(11):CD012216. doi: 10.1002/14651858.CD012216.pub2.
10
Interactions Between the Innate and Adaptive Immune Responses.先天性免疫反应与适应性免疫反应之间的相互作用
Adv Exp Med Biol. 2025;1476:297-308. doi: 10.1007/978-3-031-85340-1_12.

引用本文的文献

1
The Alzheimer's disease-associated complement receptor 1 variant confers risk by impacting glial phagocytosis.与阿尔茨海默病相关的补体受体1变体通过影响胶质细胞吞噬作用而带来风险。
Alzheimers Dement. 2025 Jul;21(7):e70458. doi: 10.1002/alz.70458.

本文引用的文献

1
Innovations in Breaking Barriers: Liposomes as Near-Perfect Drug Carriers in Ischemic Stroke Therapy.创新突破:脂质体作为缺血性脑卒中治疗中近乎完美的药物载体
Int J Nanomedicine. 2024 Apr 23;19:3715-3735. doi: 10.2147/IJN.S462194. eCollection 2024.
2
The complement system in neurodegenerative diseases.补体系统与神经退行性疾病。
Clin Sci (Lond). 2024 Mar 20;138(6):387-412. doi: 10.1042/CS20230513.
3
Targeting terminal pathway reduces brain complement activation, amyloid load and synapse loss, and improves cognition in a mouse model of dementia.
靶向终末途径可减少脑补体激活、淀粉样蛋白负荷和突触丢失,并改善痴呆小鼠模型的认知功能。
Brain Behav Immun. 2024 May;118:355-363. doi: 10.1016/j.bbi.2024.03.017. Epub 2024 Mar 12.
4
Subsequent correlated changes in complement component 3 and amyloid beta oligomers in the blood of patients with Alzheimer's disease.阿尔茨海默病患者血液中补体成分 3 和淀粉样β寡聚体的后续相关变化。
Alzheimers Dement. 2024 Apr;20(4):2731-2741. doi: 10.1002/alz.13734. Epub 2024 Feb 27.
5
Genome-Wide Association Studies of ARIA From the Aducanumab Phase 3 ENGAGE and EMERGE Studies.ARIA 的全基因组关联研究来自 aducanumab 三期 ENGAGE 和 EMERGE 研究。
Neurology. 2024 Feb 13;102(3):e207919. doi: 10.1212/WNL.0000000000207919. Epub 2023 Dec 28.
6
Efficacy and Safety of Ravulizumab, a Complement C5 Inhibitor, in Adults With Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial.补体 C5 抑制剂瑞维鲁单抗治疗肌萎缩侧索硬化症成人患者的疗效和安全性:一项随机临床试验。
JAMA Neurol. 2023 Oct 1;80(10):1089-1097. doi: 10.1001/jamaneurol.2023.2851.
7
Alzheimer's disease-associated complement gene variants influence plasma complement protein levels.阿尔茨海默病相关补体基因变异影响血浆补体蛋白水平。
J Neuroinflammation. 2023 Jul 21;20(1):169. doi: 10.1186/s12974-023-02850-6.
8
Complement C3aR depletion reverses HIF-1α-induced metabolic impairment and enhances microglial response to Aβ pathology.补体 C3aR 耗竭可逆转 HIF-1α 诱导的代谢损伤,并增强小胶质细胞对 Aβ 病理的反应。
J Clin Invest. 2023 Jun 15;133(12):e167501. doi: 10.1172/JCI167501.
9
Complement C1q-dependent excitatory and inhibitory synapse elimination by astrocytes and microglia in Alzheimer's disease mouse models.星形胶质细胞和小胶质细胞通过补体 C1q 依赖性兴奋性和抑制性突触消除在阿尔茨海默病小鼠模型中的作用。
Nat Aging. 2022 Sep;2(9):837-850. doi: 10.1038/s43587-022-00281-1. Epub 2022 Sep 20.
10
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease Therapeutics.抗淀粉样蛋白单克隆抗体是具有变革性的治疗方法,重新定义了阿尔茨海默病的治疗方法。
Drugs. 2023 May;83(7):569-576. doi: 10.1007/s40265-023-01858-9. Epub 2023 Apr 15.